Article Details

J&J Takes Lead in RSV Vaccine Race with 80% Efficacy in Phase II - PharmaLive

Retrieved on: 2021-10-04 18:22:30

Tags for this article:

Click the tags to see associated articles and topics

J&J Takes Lead in RSV Vaccine Race with 80% Efficacy in Phase II - PharmaLive. View article details on hiswai:

Excerpt

With no approved RSV vaccines, multiple companies are pushing forward to break through that barrier. Last week, AstraZeneca presented data for its RSV treatment ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up